<p>Day-5 DCs were incubated for 2 hours with inhibitors for p72 Syk, PI3K, p38 MAPK or NF-κB after which particle-bound PADRE, particle-bound P2C or soluble LPS were added and the cultures continued for 2 more days. On day 7 the cells were analyzed by flow cytometry for expression of CD80, CD86, CD83 and HLA-DR and their culture supernatant by ELISA for IL-12p70. The graphs show fold change of expression of CD80 (<b>A</b>), CD86 (<b>B</b>), CD83 (<b>C</b>) and HLA-DR (<b>D</b>), or IL-12p70 levels in the supernatants (<b>E</b>) with standard error of 7 independent experiments with cells from 7 different healthy donors. * = p<0.05; ** = p<0.01; and *** = p<0.001 comparing the group treated with stimulus only vs. the groups treated with stimu...
<p>Immature DC were cultured for 30 h in the absence (media) or in the presence of LPS (1 µg/ml), wi...
<p>(A) Representative images of co-stimulatory molecules MHC-II, CD80 and CD86 on BMDCs detected by ...
<p>iDCs (n = 5) were treated with a combination of recombinant CXCL1 (100ng/mL) and VEGF (20 ng/mL),...
<p>Effect of the PLC inhibitor D609 (<b>A</b>) and the sphingosine kinase inhibitor SKI-II (<b>B</b>...
<p>Effect of the CaMKII inhibitor CK59 on the phenotypic maturation of DCs induced by particle-bound...
<p>Day-5 DCs were collected and incubated with particle-bound PADRE, particle-bound P2C or ionomycin...
<p>iDCs were generated from adherent PBMCs depleted of T cells. The adherent cells were cultured in ...
<p>iDCs as in the experiments shown in <a href="http://www.plosone.org/article/info:doi/10.1371/jour...
The round THP-1 cells changed to be adherent flatten cells (white arrows). Under forward scatter and...
<p>iDC (n = 6) were treated with TCM of 21 colorectal cancer patients for 4 hours before adding LPS;...
<p>In panel A, B, C, D and E, DCs were used either unstimulated (NS) or in the presence of BbC50sn (...
A & B) Shown are representative flow cytometry profile and cumulative data of direct DCs pretreated ...
<p>(<b>A</b>) Light microscopy showing control differentiated DCs (Mock, panel 1) and inhibition of ...
<p>BMDC obtained after 9 days of culture with GM-CSF were infected with CFSE-labeled metacyclic prom...
<p>DCs matured as described in the methods section were labeled with anti-CD11c and either anti-CD86...
<p>Immature DC were cultured for 30 h in the absence (media) or in the presence of LPS (1 µg/ml), wi...
<p>(A) Representative images of co-stimulatory molecules MHC-II, CD80 and CD86 on BMDCs detected by ...
<p>iDCs (n = 5) were treated with a combination of recombinant CXCL1 (100ng/mL) and VEGF (20 ng/mL),...
<p>Effect of the PLC inhibitor D609 (<b>A</b>) and the sphingosine kinase inhibitor SKI-II (<b>B</b>...
<p>Effect of the CaMKII inhibitor CK59 on the phenotypic maturation of DCs induced by particle-bound...
<p>Day-5 DCs were collected and incubated with particle-bound PADRE, particle-bound P2C or ionomycin...
<p>iDCs were generated from adherent PBMCs depleted of T cells. The adherent cells were cultured in ...
<p>iDCs as in the experiments shown in <a href="http://www.plosone.org/article/info:doi/10.1371/jour...
The round THP-1 cells changed to be adherent flatten cells (white arrows). Under forward scatter and...
<p>iDC (n = 6) were treated with TCM of 21 colorectal cancer patients for 4 hours before adding LPS;...
<p>In panel A, B, C, D and E, DCs were used either unstimulated (NS) or in the presence of BbC50sn (...
A & B) Shown are representative flow cytometry profile and cumulative data of direct DCs pretreated ...
<p>(<b>A</b>) Light microscopy showing control differentiated DCs (Mock, panel 1) and inhibition of ...
<p>BMDC obtained after 9 days of culture with GM-CSF were infected with CFSE-labeled metacyclic prom...
<p>DCs matured as described in the methods section were labeled with anti-CD11c and either anti-CD86...
<p>Immature DC were cultured for 30 h in the absence (media) or in the presence of LPS (1 µg/ml), wi...
<p>(A) Representative images of co-stimulatory molecules MHC-II, CD80 and CD86 on BMDCs detected by ...
<p>iDCs (n = 5) were treated with a combination of recombinant CXCL1 (100ng/mL) and VEGF (20 ng/mL),...